John Burnett - Academia.edu (original) (raw)

Papers by John Burnett

Research paper thumbnail of Renin–Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation

Circulation-heart Failure, May 1, 2013

Research paper thumbnail of Designer Natriuretic Peptides

Journal of Investigative Medicine, 2009

Research paper thumbnail of The Effects of Nesiritide on Renal Function and Diuretic Responsiveness in Acutely Decompensated Heart Failure Patients With Renal Dysfunction

Journal of Cardiac Failure, May 1, 2008

Research paper thumbnail of Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease

Research paper thumbnail of Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications

Journal of Molecular and Cellular Cardiology, Oct 1, 2014

Research paper thumbnail of HFSA 2010 Guideline Executive Summary Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline

Research paper thumbnail of Atrial Natriuretic Peptide ― Old But New Therapeutic in Cardiovascular Diseases ―

Circulation journal, 2017

Research paper thumbnail of Evidence for Angiotensin II as a Naturally Existing Suppressor for the Natriuretic Peptide System

bioRxiv (Cold Spring Harbor Laboratory), Jan 27, 2023

Research paper thumbnail of Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide

International Journal of Cardiology, Apr 1, 2019

Research paper thumbnail of CRRL269: a novel designer and renal-enhancing pGC-A peptide activator

American Journal of Physiology-regulatory Integrative and Comparative Physiology, Mar 1, 2018

Research paper thumbnail of Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing<i>in vivo</i>and<i>ex vivo</i>actions

European Heart Journal - Cardiovascular Pharmacotherapy, Dec 10, 2015

Research paper thumbnail of Pharmacodynamics Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects

The Journal of Clinical Pharmacology, Jun 1, 2009

Research paper thumbnail of In-Vivo Evaluation of an In Situ Polymer Precipitation Delivery System for a Novel Natriuretic Peptide

Research paper thumbnail of Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology

Cardiovascular Research, Jul 16, 2021

Research paper thumbnail of Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones:biomarkers or mediators

Clinica Chimica Acta, Mar 1, 2015

Research paper thumbnail of Modulation of cGMP in Heart Failure: A New Therapeutic Paradigm

Research paper thumbnail of The Endocrine Heart

Research paper thumbnail of Membrane guanylyl cyclase receptors: an update

Trends in Endocrinology and Metabolism, Aug 1, 2006

Research paper thumbnail of Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension

Frontiers in Physiology, 2022

The heart serves as an endocrine organ producing the hormones atrial natriuretic peptide (ANP) an... more The heart serves as an endocrine organ producing the hormones atrial natriuretic peptide (ANP) and b-type natriuretic peptide (BNP) which via the guanylyl cyclase A (GC-A) receptor and the second messenger cGMP participate in blood pressure homeostasis under physiologic conditions. Genetic models of the ANP gene or the GCA receptor together with genomic medicine have solidified the concept that both cardiac hormones are fundamental for blood pressure homeostasis and when deficient or disrupted they may contribute to human hypertension. Advances in peptide engineering have led to novel peptide therapeutics including the ANP-analog MANP for human hypertension. Most importantly a first in human study of MANP in essential hypertension has demonstrated its unique properties of aldosterone suppression and blood pressure reduction. Physiology and pharmacology ultimately lead us to innovative peptide-based therapeutics to reduce the burden of cardiovascular disease.

Research paper thumbnail of Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

JACC: Basic to Translational Science, 2019